Benefits of co-administration of macrolides and glucocorticosteroids in the treatment of severe community acquired pneumonia Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies Year: 2016
Antimicrobial susceptibility of pseudomonasaeruginosa in CF patients before and after regular treatment with inhaled tobramycin Source: International Congress 2015 – Cystic fibrosis: microbiology, immunology and assessment Year: 2015
Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) in patients with pseudomonas aeruginosa Source: International Congress 2014 – Interventions and other therapeutic approaches in respiratory infections Year: 2014
Do we treat mycoplasma pneumoniae infections differently during an epidemic? Source: International Congress 2015 – Treatment and control of respiratory disease Year: 2015
Colistin therapy for nosocomial pneumonia and nephrotoxicity Source: Annual Congress 2013 –Antibiotics, resistance and vaccines Year: 2013
Multidrug resistant acinetobacter baumanii pneumonia: Mortality analysis and comparison of intravenous versus aerosolized therapy Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014
Beta lactam plus macrolide antibiotic combination therapy reduces the mortality of community-acquired pneumococcal pneumonia more than beta lactam antibiotics alone Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014
Can the broad-spectrum antibiotics improve the prognoses of high-risk nursing- and healthcare-associated pneumonia? Source: International Congress 2014 – Epidemiology, scores and outcomes of respiratory infections Year: 2014
Surfactant-enforced treatment of pseudomonas -induced pneumonia Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013
Clinical features of adults with seven-valent- conjugated-vaccine- serotype pneumococcal pneumonia Source: Annual Congress 2013 –Antibiotics, resistance and vaccines Year: 2013
Efficacy of moxifloxacin in TB resistant to isoniazid Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Frequency of multidrug resistant pathogens in healthcare associated pneumonia Source: International Congress 2014 – Resistance, bacteriological profile and comorbidities in respiratory infections Year: 2014
Haemophilus influenza related respiratory infections and hospital re-admissions Source: Annual Congress 2013 –Bacterial, fungal and mycobacterial infections Year: 2013
Survival benefit of beta-lactam plus macrolide combined therapy versus beta-lactam plus quinolones in hospitalized community-acquired pneumonia Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies Year: 2016
Empirical treatment of community-acquired pneumonia after outpatient beta-lactam therapy Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016
A multicenter study of antimicrobial resistance of clinical strains of pneumococci in Kyrgyzstan Source: International Congress 2016 – Microbiological issues and translational research in respiratory infections Year: 2016
Investigation of gram positive antibiotics as aerosol administration (cubicin, vancomycin, zyvoxid) Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014
Aminoglycoside use for pseudomonas aeruginosa in bronchiectasis Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014
Pulmonary actinomycosis: Successful treatment with oral antibiotics Source: Annual Congress 2013 –Interesting cases of respiratory infections Year: 2013
Modification of empirical antibiotic therapy in community acquired pneumonia Source: International Congress 2014 – Different interesting issues in respiratory infections: 2 Year: 2014